Analyse Amylyx Pharmaceuticals, Inc. (AMLX) — Kairos Score 63/100

À propos de Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

18 transactions — 0 achats et 11 ventes déclarés par les dirigeants de Amylyx Pharmaceuticals, Inc..

🏦 Hedge Funds

17 fonds institutionnels déclarent une position sur AMLX dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur AMLX.

• Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
• Amylyx Pharmaceuticals And 2 More Quality Growth Stocks

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.